Precious Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-11-2024
- Paid Up Capital ₹ 1.00 M
as on 15-11-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.44 M
as on 15-11-2024
- Revenue 15.70%
(FY 2023)
- Profit 52.09%
(FY 2023)
- Ebitda 16.40%
(FY 2023)
- Net Worth 13.27%
(FY 2023)
- Total Assets 0.45%
(FY 2023)
About Precious Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.44 M.
Rabi Panda, Biswajit Dash, and Nibedita Dash serve as directors at the Company.
- CIN/LLPIN
U52310OR2012PTC015157
- Company No.
015157
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Mar 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Precious Lifesciences Private Limited offer?
Precious Lifesciences Private Limited offers a wide range of products and services, including Ayurvedic Medicine, Asthma Herbal Capsule & Tablet, Pharmaceutical Syrup, Health Supplement, Herbal Sexual Health Supplement, Ayurvedic Erectile Dysfunction Capsules, Herbal Oil, Herbal Medicinal Oil, Ayurvedic Fever Tablet, Antihistamines.
Who are the key members and board of directors at Precious Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rabi Panda  | Managing Director | 27-Mar-2012 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Biswajit Dash | Director | 27-Mar-2012 | Current |
| Nibedita Dash | Director | 01-Nov-2017 | Current |
Financial Performance of Precious Lifesciences.
Precious Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.7% increase. The company also saw a substantial improvement in profitability, with a 52.09% increase in profit. The company's net worth Soared by an impressive increase of 13.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Precious Lifesciences?
In 2023, Precious Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 31 Mar 2022 | ₹1.44 M | Open |
Allahabad Bank Creation Date: 05 Feb 2016 | ₹5.00 M | Open |
How Many Employees Work at Precious Lifesciences?
Unlock and access historical data on people associated with Precious Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Precious Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Precious Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
